Blood Cancer Journal最新文献

{"title":"Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia","authors":"Betty Gration, Cameron Wellard, Elizabeth Moore, Peter Mollee, Anita Shetty, Cecily Forsyth, Jessica Heenan, Ian Kerridge, Zoe McQuilten, Erica Wood, Andrew Spencer, Georgia McCaughan","doi":"10.1038/s41408-026-01596-7","DOIUrl":"https://doi.org/10.1038/s41408-026-01596-7","url":null,"abstract":"Outcomes in multiple myeloma (MM) have improved significantly but remain heterogeneous. We assessed the impact of non-biological social determinants of health on treatment and survival outcomes in Australia using data from the Australian and New Zealand Myeloma and Related Diseases Registry. A total of 4405 patients diagnosed with MM between June 2012 and October 2025 across 44 Australian sites were assigned an area-level socioeconomic status (SES) using individual postcodes. Baseline characteristics, treatment and survival outcomes were compared across high (n = 1484), medium (n = 1463), and low (n = 1458) SES tertiles. Lower neighbourhood SES was associated with higher BMI, poorer functional status, more comorbidities (diabetes, cardiac and pulmonary disease), Asian ethnicity and greater remoteness. Independent of these baseline differences, patients from lower SES neighbourhoods were less likely to receive an autologous stem cell transplant (odds ratio = 1.1 medium vs low, p = 0.41; 1.5 high vs low, p < 0.01) and time to reach ASCT following induction was longer (p < 0.001) despite this being standard-of-care therapy with proven survival benefit. Median overall survival was shorter for the low SES group at 78.5 months compared to 92.5 months (HR = 0.85, p = 0.01) and 86.7 months (HR = 0.85, p = 0.01) for the medium and high SES groups respectively. These findings demonstrate significant disparities in treatment and outcomes favouring higher SES, independent of biological factors, within a universal healthcare system. This suggests that non-biological factors continue to influence access to standard-of-care therapy and survival, warranting further research to identify and address barriers to equitable care.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148728873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and perceptions of supplement use among patients with plasma cell disorders.","authors":"Maria A Malik, Eliana Schach, Yan Leyfman, Andriy Derkach, Francesca Castro, Jorge Arturo Hurtado Martinez, Ana M Sahagun Sanchez Aldana, Patricia Alejandra Flores Perez, Jennifer M Ahlstrom, Jay R Hydren, Saad Z Usmani, Jun J Mao, Susan Chimonas, Urvi A Shah","doi":"10.1038/s41408-026-01603-x","DOIUrl":"https://doi.org/10.1038/s41408-026-01603-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious complications following bispecific antibody or CAR T therapy in adult patients with hematologic malignancies: a retrospective database analysis","authors":"Mark Michael, Fady Mishriky, Konstantinos Ouranos, Nadine Hassan, Evangelia K. Mylona, Fadi Shehadeh, Tilemachos Koutouratsas, Diana Avila, Siddharth Das, Jenny Petkova, Eleftherios Mylonakis","doi":"10.1038/s41408-026-01599-4","DOIUrl":"https://doi.org/10.1038/s41408-026-01599-4","url":null,"abstract":"T-cell redirection therapies, including bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T therapy, have transformed the treatment of relapsed or refractory hematologic malignancies. However, comparative data on infectious complications between these treatments remain limited. We performed a propensity score-matched analysis of adults with hematologic malignancies treated with BsAbs or CAR T using the TriNetX global research network. To mitigate confounding, we utilized 1:1 propensity score matching (caliper 0.1) to balance cohorts on demographics, malignancy type, comorbidities, and prior treatments. The primary outcome was 1-year infection hazard in BsAbs vs. CAR T. We included 2 192 matched patients (1 096/group; mean age 65.8 (11.4) years for BsAbs, 65.4 (10.2) years for CAR T). Multiple myeloma was the most common malignancy (~62%). At 1 year, infection hazard was not statistically different between cohorts (BsAbs: 57% vs. CAR T: 55.9%; HR: 1.07; 95% CI: [0.96–1.20]). Early phase infection hazard (days 1–30) was lower with BsAbs but not statistically significant (HR: 0.87; 95% CI: [0.74–1.02]). However, BsAbs therapy was associated with higher infection hazard during intermediate (days 31–180; HR: 1.27; 95% CI: [1.10–1.46]) and late phases (days 181–365; HR: 1.20; 95% CI: [1.01–1.41]). In the late phase, BsAbs carried higher hazard for fungal (HR: 2.14; 95% CI: [1.26–3.64]) and viral pathogens (HR: 1.32; 95% CI: [1.02–1.73]). Respiratory tract infections were the most frequent complication and were higher with BsAbs across all time windows (1-year: 35.4% vs. 30.4%; HR: 1.32; 95% CI: [1.14–1.53]). In conclusion, among patients captured within TriNetX, the overall observed 1-year infection rate did not differ significantly between BsAbs and CAR T therapy. However, BsAbs therapy was associated with higher coded rates of late-onset infections after extensive adjustment, although residual confounding from disease severity and treatment duration remains possible. Further studies must better define this infection burden and optimize prevention strategies.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"375 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148728892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of in vivo immune remodeling in Ph⁺ all patients receiving frontline ponatinib and blinatumomab therapy.","authors":"Nadia Peragine, Michela Ansuinelli, Giulia Radice, Mariangela Di Trani, Maria Stefania De Propris, Giada Almici, Marina Parisi, Maria Paola Martelli, Daniele Mattei, Erika Borlenghi, Federico Fazio, Daniele Vallisa, Sabina Chiaretti, Anna Guarini, Robin Foà","doi":"10.1038/s41408-026-01595-8","DOIUrl":"10.1038/s41408-026-01595-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity","authors":"JE Wiedmeier-Nutor, DL Riggs, CK Stein, KK Mangalaparthi, RK Kandasamy, S. Brown, K. Franke, Y. Shotts, JC Figueroa Aguirre, YW Asmann, E. Braggio, R. Fonseca, A. Pandey, M. Chesi, PL Bergsagel","doi":"10.1038/s41408-026-01597-6","DOIUrl":"https://doi.org/10.1038/s41408-026-01597-6","url":null,"abstract":"Multiple myeloma (MM) is an incurable plasma cell neoplasm characterized by diverse and complex genetic abnormalities, including translocations of immunoglobulin (Ig) genes and a hyperdiploid karyotype. Much of our current understanding of MM genetics, epigenetics, pathogenesis and response/resistance to myeloma directed therapies originated from studies on human MM-derived cell lines (HMCL). In this study, we conducted an integrated multi-omics analysis in five hyperdiploid cell lines established from serial samples from a single relapsed/refractory hyperdiploid MM patient, enabling detailed characterization of the genetic landscape and molecular alterations through disease progression.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"6 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148728874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hair bulb and oral mucosa DNA for prompt germline testing in hematologic neoplasms.","authors":"Ferran Balbastre-Úbeda, Sara Torres-Esquius, Maria Gabarrós-Subirà, Francisco Beas, Jordi Leno-Colorado, Cristina Sanchez-Morales, Tzu Hua Chen-Liang, Susana Urban-Giral, Meritxell Tena-Alegre, Ana María Hurtado, María Jesús Casas-Tio, Ana María Garrido, Pamela Acha, Adoración Blanco, Francesc Solé, Mónica Del Rey, María Díez-Campelo, David Valcárcel, Maria Julia Montoro, Andrés Jerez","doi":"10.1038/s41408-026-01602-y","DOIUrl":"10.1038/s41408-026-01602-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities","authors":"Naroa Barrena, Edurne San José-Enériz, Luis V. Valcárcel, Danel Olaverri-Mendizabal, Estibaliz Urizar-Compains, Leire Garate, Estíbaliz Miranda, Paula Rodriguez-Marquez, Romika Kumari, Patxi San Martín-Uriz, Juan Roberto Rodriguez-Madoz, Leonor Puchades-Carrasco, Caroline A. Heckman, Paula Rodriguez-Otero, Francisco J. Planes, Xabier Agirre, Felipe Prósper","doi":"10.1038/s41408-026-01604-w","DOIUrl":"https://doi.org/10.1038/s41408-026-01604-w","url":null,"abstract":"Aberrant metabolism, a hallmark of cancer, reveals vulnerabilities across human tumors. Here, we demonstrate that transcriptomic alterations of metabolism-related genes (metabolic transcriptome) in multiple myeloma (MM), classify patients into six metabolic-transcriptional groups characterized by specific metabolic pathways and cytogenetic alterations, independent of currently described myeloma risk groups. Interestingly, hyperdiploid patients clustered into 2 groups (MM5 and MM6) with significantly distinct Progression-Free and Overall Survival. The MM5 group, with worse prognosis, showed a significant enrichment in myeloid and dormant cell signatures. Regulon analysis identified myeloid transcription factors (TFs) as regulators of metabolic, myeloid, and dormant genes in MM5. In addition to myeloid genes acting as potential biomarkers and therapeutic targets, the metabolic gene ACSL1 plays a crucial role in MM5, decreasing cell proliferation by affecting metabolism and mitochondrial function, sensitizing MM to BCL-2 family inhibitors. These findings highlight ACSL1 as a promising therapeutic target for MM5 and provide new insights into MM metabolic heterogeneity that may guide future precision medicine strategies.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"67 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148728882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity","authors":"Kenneth JC Lim, Melinda Tan, Ricardo Parrondo, Saurabh Chhabra, Christoph Schaefers, Katharine Dooley, Andre De Menezes Silva Corraes, Malvika Gupta, Darin Carabenciov, Morie Gertz, Lisa Hwa, Stephens Haily, Prashant Kapoor, Taxiarchis Kourelis, Rahma Warsame, Joselle Cook, Moritz Binder, Nadine Abdallah, Saurabh Zanwar, P. Leif Bergsagel, Udit Yadav, Erin Wiedmeier-Nutor, Susan Geyer, Sikander Ailawadhi, Rafael Fonseca, Shaji Kumar, Anastasia Zekeridou, Yi Lin","doi":"10.1038/s41408-026-01598-5","DOIUrl":"https://doi.org/10.1038/s41408-026-01598-5","url":null,"abstract":"High post-infusion absolute lymphocyte count (ALC) following ciltacabtagene autoleucel (cilta-cel) therapy is associated with an increased risk of immune effector cell–associated delayed neurotoxicity (IEC-DNT), including parkinsonism (IEC-PKS) and cranial nerve palsies (IEC-NP). Between December 2024 and August 2025, we evaluated a prophylactic strategy using a short course of dexamethasone (DEX) in 57 patients with high-ALC, defined as a post-infusion ALC of ≥3 × 10⁹/L on serial monitoring after CAR-T infusion. DEX was administered at 10 mg twice daily for a minimum of three days. Outcomes were compared with a historical control cohort of 104 patients with high-ALC treated between February 2022 and November 2024. While DEX appeared to attenuate the severity of facial nerve palsy, it did not significantly improve event-free survival for IEC-DNT, IEC-PKS, or IEC-NP, nor did it reduce the severity of IEC-PKS. Analysis of ALC kinetics demonstrated no statistically or biologically meaningful reduction in lymphocyte expansion, suggesting that the dose and duration of dexamethasone may be insufficient, or that additional immune and host factors contribute to the risk of IEC-DNT. These findings highlight the limited role of corticosteroid prophylaxis and underscore the need for more mechanistically targeted strategies to mitigate this challenging complication of BCMA-directed CAR-T therapy.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"9 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148728877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.","authors":"Hira Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli, Jawad Alrawabdeh, Marah Alzu'bi, Carolina D Schinke, Sharmilan Thanendrarajan, John D Shaughnessy, Fenghuang Zhan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi","doi":"10.1038/s41408-026-01593-w","DOIUrl":"10.1038/s41408-026-01593-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bosmolisib (BR101801), a novel PI3K-δ/γ and DNA-PK inhibitor for relapsed/refractory patients with peripheral T-cell lymphoma: a phase I study","authors":"Tae Min Kim, Seok Jin Kim, Jin Seok Kim, Deok-Hwan Yang, Dok Hyun Yoon, Won Sik Lee, Eunyoung Lee, Jeong-Ok Lee, Ahmad Hatem Mattour, Jorge Chaves, Bong-Seog Kim","doi":"10.1038/s41408-026-01600-0","DOIUrl":"https://doi.org/10.1038/s41408-026-01600-0","url":null,"abstract":"Bosmolisib is a novel triple inhibitor of PI3K-δ/γ and DNA-PK for malignancy treatment. This was a first-in-human, phase 1, open-label, dose-escalation, and dose-expansion trial with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Patients received bosmolisib orally once daily in 28-day cycles across four dose levels (50–325 mg) until disease progression or unacceptable toxicity. The study utilized a 3 + 3 dose-escalation design to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), followed by expansion at RP2D. Primary endpoints were safety and MTD/RP2D determination; secondary endpoints included efficacy, pharmacokinetics, and pharmacodynamics. A total of 26 patients were enrolled in dose-escalation (N = 12) and dose-expansion (N = 14). Median age was 65 years with a median of 3 prior therapies. Bosmolisib demonstrated acceptable tolerability; dose-limiting toxicities were observed at 325 mg (alanine transaminase [ALT] increased and erythema multiforme), establishing MTD/RP2D at 200 mg. Most adverse events (AEs) were Grade 1–2, with the most common Grade ≥3 AEs (ALT 23.1%, aspartate transaminase 15.4%). Of 23 evaluable patients, the overall response rate (ORR) was 26.1%, and in PTCL patients, ORR was 31.6% with one patient achieving a durable complete response. Pharmacodynamics profiling showed statistically significant decrease in regulatory T-cells. These findings support evaluation of bosmolisib in a phase 2 trial (ClinicalTrials.gov number, NCT04018248).","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148693502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}